The SARS-CoV-2 Spike protein is often the main target of COVID-19 therapeutic research efforts. Yet, numerous other structural and non-structural proteins (NSPs) comprise the SARS-CoV-2 virus. A greater understanding of coronavirus-related antigens is critical for optimizing the research, development, and manufacturing of novel therapeutics and robust diagnostics. In this webinar sponsored by R&D Systems, part of the Bio-Techne Corporation, Anthony Person will discuss novel protein-based assays for COVID-19 and how they can advance diagnostic and therapeutic development.

Topics to be covered

-Newly discovered genetic Spike variants, Spike glycosylation, ACE-2, proteases, and non NSPs
-How new protein-based tools can help advance the development of clinical applications

  • 1609861766-48394f9b676330ca
    Anthony Person, PhD
    Sr. Director, Protein Business Unit, Bio-Techne
    Anthony Person worked in the stem cell and biotech industry for over 13 years, where he developed methods for cellular reprogramming using mRNA overexpression approaches. In 2018, Dr. Person joined R&D Systems as a leader in protein development. Pearson’s team develops novel products that expand R&D System’s portfolio of proteins for Immuno-Oncology, Regenerative Medicine, and most recently Coronavirus-related research applications.